Left Brain Wealth Management LLC Invests $244,000 in Astera Labs, Inc. $ALAB

Left Brain Wealth Management LLC bought a new stake in Astera Labs, Inc. (NASDAQ:ALAB) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 2,700 shares of the company’s stock, valued at approximately $244,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Sierra Summit Advisors LLC lifted its position in Astera Labs by 17.0% in the second quarter. Sierra Summit Advisors LLC now owns 110,974 shares of the company’s stock valued at $10,034,000 after acquiring an additional 16,140 shares during the last quarter. American Century Companies Inc. increased its position in shares of Astera Labs by 383.4% during the second quarter. American Century Companies Inc. now owns 32,791 shares of the company’s stock worth $2,965,000 after purchasing an additional 26,008 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Astera Labs by 51.3% in the 2nd quarter. Rhumbline Advisers now owns 157,884 shares of the company’s stock valued at $14,276,000 after purchasing an additional 53,539 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Astera Labs by 10.3% in the 2nd quarter. Franklin Resources Inc. now owns 184,858 shares of the company’s stock valued at $16,715,000 after purchasing an additional 17,307 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in shares of Astera Labs by 40.6% in the 2nd quarter. Legal & General Group Plc now owns 358,545 shares of the company’s stock valued at $32,420,000 after purchasing an additional 103,507 shares during the period. 60.47% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Astera Labs

In other Astera Labs news, CEO Jitendra Mohan sold 90,459 shares of Astera Labs stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $144.69, for a total value of $13,088,512.71. Following the sale, the chief executive officer owned 2,080,418 shares of the company’s stock, valued at approximately $301,015,680.42. The trade was a 4.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Manuel Alba sold 183,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $173.27, for a total value of $31,708,410.00. Following the transaction, the director directly owned 385,863 shares of the company’s stock, valued at approximately $66,858,482.01. This trade represents a 32.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 619,436 shares of company stock valued at $96,530,060. Insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ALAB. Roth Capital lifted their price target on Astera Labs from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Stifel Nicolaus increased their price objective on Astera Labs from $185.00 to $200.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Needham & Company LLC lifted their target price on shares of Astera Labs from $205.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Wall Street Zen downgraded shares of Astera Labs from a “buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Astera Labs in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, Astera Labs presently has a consensus rating of “Moderate Buy” and a consensus price target of $187.06.

Astera Labs Trading Up 1.8%

NASDAQ:ALAB opened at $141.80 on Friday. Astera Labs, Inc. has a 12-month low of $47.13 and a 12-month high of $262.90. The stock’s 50 day simple moving average is $185.11 and its 200-day simple moving average is $146.27. The firm has a market cap of $23.95 billion, a P/E ratio of 127.75, a PEG ratio of 2.64 and a beta of 1.37.

Astera Labs (NASDAQ:ALAB) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.10. The firm had revenue of $230.58 million for the quarter, compared to analyst estimates of $206.42 million. Astera Labs had a net margin of 27.50% and a return on equity of 13.48%. Astera Labs’s quarterly revenue was up 103.9% on a year-over-year basis. During the same period last year, the firm posted $0.23 EPS. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. Research analysts forecast that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Astera Labs Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.